Abstract
Newswise — Immune checkpoint inhibitors (ICI) can cause myocarditis, leaving physicians uncertain regarding the safety of restarting ICIs after recovery. This study aims to measure real-world incidence of ICI-induced myocarditis, and whether re-exposure to ICI after myocarditis impacts all-cause mortality. Adult patients with cancer treated with ICIs were identified from TriNetX network and outcomes were compared between patients re-exposed to ICI and those who were not.
Keywords: Immune-checkpoint inhibitors; cytotoxic T-lymphocyte-associated protein 4 inhibitors; lymphocyte-activation gene 3 inhibitors; myocarditis; programmed cell death protein 1/programmed cell death ligand 1 inhibitors; real-world data.
https%3A%2F%2Fwww.newswise.com%2Farticles%2Fimmune-checkpoint-inhibitor-induced-myocarditis-and-outcomes-after-re-exposure%2F%3Fsc%3Drsla
